Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well sunitinib works when given before and after surgery in treating patients with stage IV kidney cancer.

Conditions

• Kidney Cancer

Interventions

DRUG

motexafin gadolinium

DRUG

sunitinib malate

GENETIC

comparative genomic hybridization

GENETIC

gene expression analysis

GENETIC

mutation analysis

GENETIC

polymorphism analysis

OTHER

immunohistochemistry staining method

OTHER

iodine I-124 girentuximab

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

adjuvant therapy

PROCEDURE

neoadjuvant therapy

PROCEDURE

therapeutic conventional surgery

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Abramson Cancer Center at Penn Medicine

  lead OTHER

Principal Investigators

• Keith T. Flaherty, MD · Abramson Cancer Center at Penn Medicine

Study Design

Purpose

TREATMENT

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-06-30

Primary Completion

2010-07-31

Countries

• United States

Study Locations